The Daily Ledger

Current AffairsNews

India Unveils First Indigenous H5N1 Vaccine for Chickens in Bhopal

India has unveiled its first domestically developed inactivated H5N1 vaccine for chickens, targeting clade 2.3.2.1a. Developed by ICAR-NIHSAD in Bhopal, the technology is intended to strengthen poultry disease control, though commercial rollout, pricing and vaccination policy details remain to be announced.

The Daily Ledger Staff4 min read
A scientist in a modern animal-health laboratory examines a vaccine vial beside a clean poultry research enclosure.
Illustration generated with AI

India has unveiled its first indigenous inactivated vaccine for chickens against the H5N1 strain of highly pathogenic avian influenza, marking a development in the country’s efforts to strengthen poultry disease control. The vaccine was developed by the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal and is designed to target H5N1 clade 2.3.2.1a.

Union Agriculture and Farmers’ Welfare Minister Shivraj Singh Chouhan dedicated the vaccine technology at the institute in Bhopal on November 20. The development addresses a gap identified by the Agriculture Ministry: no specific commercial vaccine had been available for the H5N1 clade 2.3.2.1a circulating in India’s poultry sector.

What the vaccine is designed to target

The vaccine is an inactivated preparation intended for chickens and targets the H5N1 virus belonging to clade 2.3.2.1a. A clade is a genetic grouping within a virus family. The Ministry of Agriculture has said this particular H5N1 clade has been responsible for most bird flu outbreaks in chickens in India, making it a priority for disease-control research.

The institute’s work is focused on the poultry disease rather than human vaccination. The announcement does not describe this as a vaccine for people, nor does it establish a new human treatment or immunisation programme. Its stated purpose is to support protection of chickens against the targeted avian influenza strain.

Why poultry disease control matters

Highly pathogenic avian influenza can cause severe losses in poultry populations. Outbreaks may lead to large-scale culling, movement restrictions and trade disruptions, affecting farmers, hatcheries, processors and businesses linked to poultry production. The Agriculture Ministry said India has recorded more than 500 combined outbreaks of H5N1 and H5N8 since the disease was first detected in the country in 2006.

The ministry also cited estimated direct and indirect losses of ₹2,200 crore to ₹3,000 crore from the 2006 outbreak. Such figures illustrate why disease prevention and preparedness are important to the poultry sector, which supports farm livelihoods and contributes to the supply of eggs and meat.

Research and technology transfer

ICAR-NIHSAD, based in Bhopal, developed the vaccine technology. The November 20 programme included its formal dedication and technology-transfer activity, with the stated objective of making the research available for wider use by the poultry sector. Technology transfer can create a pathway for commercial production, but it does not by itself mean that doses are already available to farmers nationwide.

The Times of India reported that institute scientists said experimental trials showed protection in chickens for up to six months and prevented transmission to contact chickens. Those trial details are attributed to the institute through the newspaper’s report. The Ministry’s original announcement identifies the vaccine and its target clade but does not publish a full trial dataset, dose schedule or field-performance results.

What is still not confirmed

Several practical details remain open in the public announcements reviewed for this report. They do not specify the commercial manufacturer, production capacity, price per dose, supply schedule or the date on which poultry farmers will be able to obtain the vaccine. The government has also not set out a nationwide vaccination policy or explained how vaccination would operate alongside existing outbreak surveillance and response measures.

These distinctions matter because a research milestone and a nationwide disease-control programme are separate steps. Commercial production, regulatory permissions, supply logistics and guidance for poultry farms will determine how quickly the technology can be used at scale. Farmers should continue to follow instructions issued by animal husbandry and veterinary authorities rather than assume that the new vaccine is immediately available for routine use.

A domestic research milestone for the poultry sector

The vaccine represents an indigenous research effort directed at a specific H5N1 strain for which the ministry said no matching commercial vaccine was available. Its potential value will depend on how the technology moves from the research institute into production and whether a clear deployment framework is established.

For now, the confirmed development is the unveiling and technology transfer of ICAR-NIHSAD’s inactivated H5N1 clade 2.3.2.1a chicken vaccine. The next stage will be to clarify manufacturing, regulatory and field-use arrangements so that poultry farmers can understand when and how it may become part of India’s wider avian influenza control strategy.

Sources

This story was prepared with the help of automated drafting tools and was reviewed and fact-checked by our editors before publication. See our Editorial Policy.

Report a problem with this story · Copyright & takedown